29 August 2017Asia

AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Second Circuit says Takeda can’t dodge two antitrust suits

26 August 2021 The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

Generics

Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug

5 August 2021 Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

1 July 2021 Takeda Pharmaceuticals organised a pay-for-delay deal with Par Pharmaceuticals to prevent a generic version of its constipation treatment from releasing, according to a complaint submitted to the US District Court for the District of Massachusetts.

More on this story

Generics

Second Circuit says Takeda can’t dodge two antitrust suits

26 August 2021 The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

Generics

Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug

5 August 2021 Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par

More on this story

Generics

Second Circuit says Takeda can’t dodge two antitrust suits

26 August 2021 The US Court of Appeals for the Second Circuit has denied an appeal from Takeda Pharmaceuticals to shut down two antitrust suits related to its diabetes drug Actos.

Generics

Takeda faces ‘pay-for-delay’ class-action suit over anti-constipation drug

5 August 2021 Takeda Pharmaceuticals is the target of a proposed class action that alleges the pharma giant paid to keep a generic anti-constipation drug off the market.

Generics

Class-action accuses Takeda of ‘pay-for-delay’ deal with Par